Nyrada Inc. (ASX:NYR)
Australia · Delayed Price · Currency is AUD 0.7700
-0.0400 (-4.94%)
Feb 11, 2026, 10:56 AM AEST
Nyrada Revenue
In the fiscal year ending June 30, 2025, Nyrada had annual revenue of 2.40M AUD, down -26.07%. Nyrada had revenue of 1.60M in the half year ending June 30, 2025, with 196.67% growth.
Revenue
2.40M
Revenue Growth
-26.07%
P/S Ratio
82.78
Revenue / Employee
n/a
Employees
n/a
Market Cap
198.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.40M | -845.19K | -26.07% |
| Jun 30, 2024 | 3.24M | 1.81M | 126.72% |
| Jun 30, 2023 | 1.43M | 336.16K | 30.73% |
| Jun 30, 2022 | 1.09M | -1.24M | -53.18% |
| Jun 30, 2021 | 2.34M | 1.21M | 107.57% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthocell | 7.55M |
| Recce Pharmaceuticals | 7.51M |
| Starpharma Holdings | 5.85M |
| Botanix Pharmaceuticals | 5.79M |
| Dimerix | 5.59M |
| Actinogen Medical | 5.49M |
| Alterity Therapeutics | 5.44M |
| Arovella Therapeutics | 3.44M |